RAGE gene polymorphisms in patients with multiple sclerosis

Zoltán Tiszlavicz, Zsofia Gyulai, K. Bencsik, Z. Szolnoki, Ágnes Katalin Kocsis, F. Somogyvári, L. Vécsei, Y. Mándi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The pathogenesis of multiple sclerosis (MS), a devastating neuroinflammatory disorder of the central nervous system, has been presumed to involve the possible importance of the receptor for advanced glycation end products (RAGE). The aim of this study was to investigate the relevance of the genetic polymorphisms of RAGE in MS patients. A total of 168 patients with MS were enrolled; 136 healthy blood donors served as controls. The-374 T/A,-479 T/C, and the G82S polymorphisms of RAGE were determined by restriction fragment length polymorphism (RFLP). There was a significant difference in RAGE-374 T/A genotype distribution between the controls and the MS patients. The AA homozygote variants were detected in 8% of the patients with MS, as compared with 19% of healthy controls (OR=2.75; 95% CI=1.319-5.733, p=0.007). No differences were observed between the MS patients and the controls, concerning the frequencies of the-479 T/C and G82S genotypes of the RAGE. Our results revealed an association between the-374 T/A polymorphism of the RAGE promoter and MS. The genetic variant-374 AA (which has previously been shown to exert significant effects on transcriptional activity) can be considered a preventive factor as regards the occurrence of MS. Our findings support the view that RAGE plays a role in the development of MS.

Original languageEnglish
Pages (from-to)360-365
Number of pages6
JournalJournal of Molecular Neuroscience
Volume39
Issue number3
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Multiple Sclerosis
Genes
Genotype
Advanced Glycosylation End Product-Specific Receptor
Central Nervous System Diseases
Homozygote
Genetic Polymorphisms
Blood Donors
Restriction Fragment Length Polymorphisms

Keywords

  • -374 T/A
  • -429 T/C
  • G82S
  • Multiple sclerosis
  • RAGE
  • RFLP
  • SNP

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

RAGE gene polymorphisms in patients with multiple sclerosis. / Tiszlavicz, Zoltán; Gyulai, Zsofia; Bencsik, K.; Szolnoki, Z.; Kocsis, Ágnes Katalin; Somogyvári, F.; Vécsei, L.; Mándi, Y.

In: Journal of Molecular Neuroscience, Vol. 39, No. 3, 11.2009, p. 360-365.

Research output: Contribution to journalArticle

@article{1735a4815235412083daf376efd489a5,
title = "RAGE gene polymorphisms in patients with multiple sclerosis",
abstract = "The pathogenesis of multiple sclerosis (MS), a devastating neuroinflammatory disorder of the central nervous system, has been presumed to involve the possible importance of the receptor for advanced glycation end products (RAGE). The aim of this study was to investigate the relevance of the genetic polymorphisms of RAGE in MS patients. A total of 168 patients with MS were enrolled; 136 healthy blood donors served as controls. The-374 T/A,-479 T/C, and the G82S polymorphisms of RAGE were determined by restriction fragment length polymorphism (RFLP). There was a significant difference in RAGE-374 T/A genotype distribution between the controls and the MS patients. The AA homozygote variants were detected in 8{\%} of the patients with MS, as compared with 19{\%} of healthy controls (OR=2.75; 95{\%} CI=1.319-5.733, p=0.007). No differences were observed between the MS patients and the controls, concerning the frequencies of the-479 T/C and G82S genotypes of the RAGE. Our results revealed an association between the-374 T/A polymorphism of the RAGE promoter and MS. The genetic variant-374 AA (which has previously been shown to exert significant effects on transcriptional activity) can be considered a preventive factor as regards the occurrence of MS. Our findings support the view that RAGE plays a role in the development of MS.",
keywords = "-374 T/A, -429 T/C, G82S, Multiple sclerosis, RAGE, RFLP, SNP",
author = "Zolt{\'a}n Tiszlavicz and Zsofia Gyulai and K. Bencsik and Z. Szolnoki and Kocsis, {{\'A}gnes Katalin} and F. Somogyv{\'a}ri and L. V{\'e}csei and Y. M{\'a}ndi",
year = "2009",
month = "11",
doi = "10.1007/s12031-009-9291-7",
language = "English",
volume = "39",
pages = "360--365",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - RAGE gene polymorphisms in patients with multiple sclerosis

AU - Tiszlavicz, Zoltán

AU - Gyulai, Zsofia

AU - Bencsik, K.

AU - Szolnoki, Z.

AU - Kocsis, Ágnes Katalin

AU - Somogyvári, F.

AU - Vécsei, L.

AU - Mándi, Y.

PY - 2009/11

Y1 - 2009/11

N2 - The pathogenesis of multiple sclerosis (MS), a devastating neuroinflammatory disorder of the central nervous system, has been presumed to involve the possible importance of the receptor for advanced glycation end products (RAGE). The aim of this study was to investigate the relevance of the genetic polymorphisms of RAGE in MS patients. A total of 168 patients with MS were enrolled; 136 healthy blood donors served as controls. The-374 T/A,-479 T/C, and the G82S polymorphisms of RAGE were determined by restriction fragment length polymorphism (RFLP). There was a significant difference in RAGE-374 T/A genotype distribution between the controls and the MS patients. The AA homozygote variants were detected in 8% of the patients with MS, as compared with 19% of healthy controls (OR=2.75; 95% CI=1.319-5.733, p=0.007). No differences were observed between the MS patients and the controls, concerning the frequencies of the-479 T/C and G82S genotypes of the RAGE. Our results revealed an association between the-374 T/A polymorphism of the RAGE promoter and MS. The genetic variant-374 AA (which has previously been shown to exert significant effects on transcriptional activity) can be considered a preventive factor as regards the occurrence of MS. Our findings support the view that RAGE plays a role in the development of MS.

AB - The pathogenesis of multiple sclerosis (MS), a devastating neuroinflammatory disorder of the central nervous system, has been presumed to involve the possible importance of the receptor for advanced glycation end products (RAGE). The aim of this study was to investigate the relevance of the genetic polymorphisms of RAGE in MS patients. A total of 168 patients with MS were enrolled; 136 healthy blood donors served as controls. The-374 T/A,-479 T/C, and the G82S polymorphisms of RAGE were determined by restriction fragment length polymorphism (RFLP). There was a significant difference in RAGE-374 T/A genotype distribution between the controls and the MS patients. The AA homozygote variants were detected in 8% of the patients with MS, as compared with 19% of healthy controls (OR=2.75; 95% CI=1.319-5.733, p=0.007). No differences were observed between the MS patients and the controls, concerning the frequencies of the-479 T/C and G82S genotypes of the RAGE. Our results revealed an association between the-374 T/A polymorphism of the RAGE promoter and MS. The genetic variant-374 AA (which has previously been shown to exert significant effects on transcriptional activity) can be considered a preventive factor as regards the occurrence of MS. Our findings support the view that RAGE plays a role in the development of MS.

KW - -374 T/A

KW - -429 T/C

KW - G82S

KW - Multiple sclerosis

KW - RAGE

KW - RFLP

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=73849149083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849149083&partnerID=8YFLogxK

U2 - 10.1007/s12031-009-9291-7

DO - 10.1007/s12031-009-9291-7

M3 - Article

C2 - 19757202

AN - SCOPUS:73849149083

VL - 39

SP - 360

EP - 365

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 3

ER -